• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Acute Trigeminal Neuralgia Associated with Initiation of Emtricitabine/Tenofovir for HIV Pre-Exposure Prophylaxis.与恩曲他滨/替诺福韦用于HIV暴露前预防起始治疗相关的急性三叉神经痛
J Int Assoc Provid AIDS Care. 2018 Jan-Dec;17:2325958218760846. doi: 10.1177/2325958218760846.
2
Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?我们应该担心替诺福韦/恩曲他滨暴露前预防产生的耐药性吗？
Curr Opin HIV AIDS. 2016 Jan;11(1):49-55. doi: 10.1097/COH.0000000000000209.
3
Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.恩曲他滨/替诺福韦对HIV阴性者骨矿物质密度影响的随机双盲安慰剂对照试验
Clin Infect Dis. 2015 Aug 15;61(4):572-80. doi: 10.1093/cid/civ324. Epub 2015 Apr 23.
4
Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.对于未感染艾滋病毒的青春期男孩和年轻男性，在用于艾滋病毒暴露前预防时，富马酸替诺福韦二吡呋酯/恩曲他滨导致的骨量下降与无肾功能损害情况下的激素变化有关。
Clin Infect Dis. 2017 Feb 1;64(3):317-325. doi: 10.1093/cid/ciw765. Epub 2016 Nov 15.
5
InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.InterPrEP：伦敦地区基于互联网的通用替诺福韦二吡呋酯/恩曲他滨预先暴露预防 - 药代动力学、安全性和结果分析。
HIV Med. 2018 Jan;19(1):1-6. doi: 10.1111/hiv.12528. Epub 2017 Jun 28.
6
Acute facial neuralgia related to initiation of emtricitabine/tenofovir for HIV PrEP: a report of two cases in a PrEP demonstration trial.因启动 HIV 暴露前预防（PrEP）而导致的急性面部神经痛：一项 PrEP 试验中两例病例报告。
Sex Health. 2024 Jan;21. doi: 10.1071/SH23129.
7
Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.通过设计用于预防 HIV-1 的 pod-intravaginal 环来输送单一、双重和三重抗逆转录病毒药物配方的安全性和药代动力学：一项 I 期试验。
PLoS Med. 2018 Sep 28;15(9):e1002655. doi: 10.1371/journal.pmed.1002655. eCollection 2018 Sep.
8
Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana.在博茨瓦纳进行的一项随机试验中，对未感染艾滋病毒的年轻成年人使用替诺福韦-恩曲他滨或安慰剂进行暴露前预防，观察其骨矿物质密度的变化。
PLoS One. 2014 Mar 13;9(3):e90111. doi: 10.1371/journal.pone.0090111. eCollection 2014.
9
Kidney function and daily emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis against HIV: results from the real-life multicentric demonstrative project PrEP Brazil.肾功能与每日恩曲他滨/替诺福韦二吡呋酯用于 HIV 暴露前预防：来自真实世界多中心示范性项目 PrEP Brazil 的结果。
AIDS Res Ther. 2022 Feb 24;19(1):12. doi: 10.1186/s12981-022-00437-4.
10
Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.美国暴露前预防项目中，每日使用替诺福韦二吡呋酯/恩曲他滨对肾功能变化的影响。
J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):193-198. doi: 10.1097/QAI.0000000000001566.

本文引用的文献

1
HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans.HIV暴露前预防（PrEP）：关于人类口服全身性HIV PrEP的现有知识综述
Infection. 2016 Apr;44(2):151-8. doi: 10.1007/s15010-015-0850-2. Epub 2015 Oct 15.
2
The role of healthcare providers in the roll out of preexposure prophylaxis.医疗服务提供者在暴露前预防推广中的作用。
Curr Opin HIV AIDS. 2016 Jan;11(1):41-8. doi: 10.1097/COH.0000000000000206.
3
Neurological syndrome in an HIV-prevention trial participant randomized to daily tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) in Bondo, Kenya.在肯尼亚邦多一项艾滋病预防试验中，一名随机接受每日替诺福韦酯（300毫克）和恩曲他滨（200毫克）治疗的参与者出现了神经综合征。
Int Med Case Rep J. 2013 Nov 29;6:91-3. doi: 10.2147/IMCRJ.S52015. eCollection 2013.
4
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).对于病毒学控制良好的患者，换用拉替拉韦联合替诺福韦/恩曲他滨或阿巴卡韦/拉米夫定治疗的安全性和有效性：一项随机试点研究（拉替拉韦因毒性或不良事件换药研究，RASTA研究）的48周结果
Scand J Infect Dis. 2014 Jan;46(1):34-45. doi: 10.3109/00365548.2013.840920. Epub 2013 Oct 28.
5
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.男男性行为人群 HIV 预防的暴露前药物预防。
N Engl J Med. 2010 Dec 30;363(27):2587-99. doi: 10.1056/NEJMoa1011205. Epub 2010 Nov 23.
6
Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study.接受抗逆转录病毒治疗的患者发生严重高乳酸血症的危险因素和临床特征：一项病例对照研究。
HIV Med. 2010 Feb;11(2):121-9. doi: 10.1111/j.1468-1293.2009.00754.x. Epub 2009 Aug 20.
7
"One pill, once daily": what clinicians need to know about Atriplatrade mark.“每日一片”：临床医生需要了解的关于 Atripla 的信息。
Ther Clin Risk Manag. 2008 Apr;4(2):291-302. doi: 10.2147/tcrm.s1708.
8
Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial.替诺福韦酯用于预防女性HIV感染：一项2期双盲随机安慰剂对照试验。
PLoS Clin Trials. 2007 May 25;2(5):e27. doi: 10.1371/journal.pctr.0020027.
9
Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy.症状性高乳酸血症：抗逆转录病毒治疗的一种新出现的并发症。
AIDS. 2000 Dec 1;14(17):2723-30. doi: 10.1097/00002030-200012010-00012.

与恩曲他滨/替诺福韦用于HIV暴露前预防起始治疗相关的急性三叉神经痛

Acute Trigeminal Neuralgia Associated with Initiation of Emtricitabine/Tenofovir for HIV Pre-Exposure Prophylaxis.

作者信息

Van Slyke Loraine, Scott Mia

机构信息

1 APEX Research/Family Medicine, Denver, CO, USA.

出版信息

J Int Assoc Provid AIDS Care. 2018 Jan-Dec;17:2325958218760846. doi: 10.1177/2325958218760846.

DOI:10.1177/2325958218760846
PMID:29534653
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6748473/
Abstract

HIV pre-exposure prophylaxis (PrEP) with emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) fixed-dose combination (FTC/TDF) is undergoing rapid scale-up in the United States. While FTC/TDF is typically well tolerated, to our knowledge, cranial nerve pathology associated with FTC/TDF has not been previously described. We report the case of a 35-year-old patient who began FTC/TDF PrEP and developed acute trigeminal neuralgia. The neurologic symptoms resolved after treatment discontinuation and recurred upon rechallenge, resulting in permanent discontinuation of PrEP treatment.

摘要

在美国，恩曲他滨（FTC）和替诺福韦酯（TDF）的固定剂量组合（FTC/TDF）用于艾滋病病毒暴露前预防（PrEP）正在迅速扩大规模。虽然FTC/TDF通常耐受性良好，但据我们所知，此前尚未描述过与FTC/TDF相关的颅神经病变。我们报告了一名35岁患者的病例，该患者开始使用FTC/TDF进行PrEP并出现急性三叉神经痛。停药后神经症状缓解，再次用药时复发，导致PrEP治疗永久停药。